1-[溴-(2-氯苯基)甲基]-2-氯苯 | 200868-49-1

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类卤化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[溴-(2-氯苯基)甲基]-2-氯苯
• 英文名称: bis-(2-chlorophenyl)-bromomethane
• 英文别名: 2,2'-dichloro-benzhydryl bromide；bis(2-chloro-phenyl)-bromo-methane；bis(2-chlorophenyl)-bromomethane；1-[bromo-(2-chlorophenyl)methyl]-2-chlorobenzene
• CAS: 200868-49-1
• 化学式: C₁₃H₉BrCl₂
• 分子量: 316.024
• InChiKey: OTOZCOKGPNCTHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-[溴-(2-氯苯基)甲基]-2-氯苯 在 potassium carbonate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成 4-(2-(Aminomethyl)phenyl)-1-(bis(2-chlorophenyl)methyl)piperidin-4-ol
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2

  摘要：

  A series of 4-[2-(aminomethyl)phenyl]-1-[bis(2-chlorophenyl)methyl]-4-hydroxypiperidine analogs has been identified as nociceptin receptor ligands. These compounds display high affinity and functional activity at the nociceptin receptor. The synthesis and structure-activity relationships at the C-4 phenyl and N-1 positions are described and the antitussive activity of a selected compound is reported. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.062
• 作为产物：
  描述：

  双(2-氯苯基)甲醇 在 二溴亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 1-[溴-(2-氯苯基)甲基]-2-氯苯
  参考文献：
  名称：

  WO2007/53435

  摘要：

  公开号：

文献信息

• Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols
  申请人：Mergelsberg Ingrid

  公开号：US20060058343A1

  公开（公告）日：2006-03-16

  The present invention relates to a process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols having the structural formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R is benzyl, R 5 -benzyl, allyl, —C(O)R 6 , —C(O)OR 8 or —CH(R 7 ) 2 ; R 1 is optionally substituted aryl or optionally substituted heteroaryl; and R 5 , R 6 , R 7 and R 8 are as defined in the specification; comprising a) reacting an amine of formula II R—NH 2 II with 2,5-dimethoxytetrahydrofuran or HC(O)(CH 2 ) 2 C(O)H, and C(O)(CH 2 C(O)OR 4 ) 2 , wherein R 4 is H or alkyl, to obtain a compound of formula III b) reacting a compound of formula III with I-R 1 , alkyl lithium, and optionally a lithium salt, to obtain a compound of formula I; and c) optionally converting a compound of formula I wherein R is benzyl, R 5 -benzyl, allyl, —C(O)R 6 or —C(O)OR 6 to a compound of formula I wherein R is —CH(R 7 ) 2 . Intermediates in the process are also claimed.

  本发明涉及一种制备具有结构式I的取代8-氮杂双环[3.2.1]辛烷-3-醇或其药用可接受盐或溶剂的方法，其中R为苄基、R5-苄基、烯丙基、—C(O)R6、—C(O)OR8或—CH(R7)2；R1为可选择取代的芳基或可选择取代的杂芳基；以及R5、R6、R7和R8如规范中所定义；包括a)将式II的胺R—NH2与2,5-二甲氧基四氢呋喃或HC(O)(CH2)2C(O)H以及C(O)(CH2C(O)OR4)2反应，其中R4为H或烷基，以获得式III的化合物；b)将式III的化合物与I-R1、烷基锂和可选择的锂盐反应，以获得式I的化合物；以及c)可选择地将式I的化合物（其中R为苄基、R5-苄基、烯丙基、—C(O)R6或—C(O)OR6）转化为式I的化合物（其中R为—CH(R7)2）。该方法中的中间体也受到保护。
• Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
  申请人：Klinge Pharma GmbH

  公开号：US06451816B1

  公开（公告）日：2002-09-17

  The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.

  该发明涉及根据通式(I)中的具有药理学价值的吡啶基烷、吡啶基烯和/或吡啶基炔酸酰胺在肿瘤治疗或免疫抑制中的使用。
• Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1
  申请人：Schering Corporation

  公开号：US20030119847A1

  公开（公告）日：2003-06-26

  Novel compounds of the formula 1 wherein R is optionally substituted heteroaryl or 2 R 1 is H or C 1 —C 6 alkyl; and R 2 and R 3 are —CH 3 , —OCH 3 or halo; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.

  公开了具有以下结构的新化合物： 其中R是可选择取代的杂环烷基或2R1为H或C1—C6烷基；以及R2和R3为—CH3，—OCH3或卤素；或其药学上可接受的盐或溶剂，以及相应的药物组合物，以及所述化合物在治疗疼痛、焦虑、咳嗽、哮喘、抑郁症和酒精滥用中的用途。
• Pyridyl alkane acid amides as cytostatics and immunosupressives
  申请人：Klinge Pharma GmbH

  公开号：US20030162972A1

  公开（公告）日：2003-08-28

  The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression. 1

  该发明涉及按照通式（I）的新吡啶基烷基酸酰胺，以及其生产方法，含有这些化合物的药物以及它们在医学上的应用，特别是在肿瘤治疗或免疫抑制方面的用途。
• The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety
  作者：Ginny D. Ho、John Anthes、Ana Bercovici、John P. Caldwell、Kuo-Chi Cheng、Xiaoming Cui、Ahmad Fawzi、Xiomara Fernandez、William J. Greenlee、John Hey、Walter Korfmacher、Sherry X. Lu、Robbie L. McLeod、Fay Ng、April Smith Torhan、Zheng Tan、Deen Tulshian、Geoffrey B. Varty、Xiaoying Xu、Hongtao Zhang

  DOI：10.1016/j.bmcl.2009.03.031

  日期：2009.5

  has led to the synthesis of a series of tropane (8-methyl-8-azabicyclo[3.2.1]octane) derivatives as optimized ligands. These compounds exhibit high affinity for the nociceptin receptor, moderate to excellent selectivity over the opioid μ receptor, and behave as full agonists. In this Letter, we present the synthesis and highlight the structure–activity relationship of tropane derivatives culminating in

  1作为Nociceptin受体的高亲和力配体的发现导致合成了一系列作为优化配体的托烷（8-甲基-8-氮杂双环[3.2.1]辛烷）衍生物。这些化合物对伤害感受器受体具有高亲和力，对阿片样物质μ受体的选择性中等至极好，并且表现为完全激动剂。在这封信中，我们介绍了合成方法并强调了托烷衍生物的结构-活性关系，最终确定了24和32为有效和口服活性的镇咳药和抗焦虑药。公开了预测人中潜在的3A4诱导的体外和体内活性，药代动力学概况和hPXR活性。